OMEROS CORP Cash and Cash Equivalents, Period Increase (Decrease)
OMEROS CORP (OMER) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$1.81 million for the 3-month period ending 2019-03-31, per its 10-Q filed 2019-05-09.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2019-05-09
- OMEROS CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$1.81M.
- OMEROS CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2018-12-31 was $3.07M, a 29.81% increase year-over-year.
- OMEROS CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2018-09-30 was -$96.00K.
- OMEROS CORP cash and cash equivalents, period increase (decrease) for the quarter ending 2018-06-30 was $1.69M, a 19.49% decline year-over-year.
- OMEROS CORP cash and cash equivalents, period increase (decrease) for fiscal 2018 was $2.47M, a 110.85% increase from fiscal 2017.
- OMEROS CORP cash and cash equivalents, period increase (decrease) for fiscal 2017 was $1.17M, a 36.20% increase from fiscal 2016.
- OMEROS CORP cash and cash equivalents, period increase (decrease) for fiscal 2016 was $859.00K, a 15.03% decline from fiscal 2015.
- OMEROS CORP cash and cash equivalents, period increase (decrease) for fiscal 2015 was $1.01M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 204 month | Cash and Cash Equivalents, Period Increase (Decrease) 207 month |
|---|---|---|---|---|---|---|
| 2019-03-31 | -$1.81M 10-Q · filed 2019-05-09 | $1.27M derived: sum of 2 quarters · filed 2019-05-09 | $1.17M derived: sum of 3 quarters · filed 2019-05-09 | $2.87M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2018-12-31 | $3.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $2.98M derived: sum of 2 quarters · filed 2019-03-01 | $4.67M derived: sum of 3 quarters · filed 2019-03-01 | $2.47M 10-K · filed 2019-03-01 | ||
| 2018-09-30 | -$96.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | $1.60M derived: sum of 2 quarters · filed 2018-11-08 | -$607.00K 10-Q · filed 2018-11-08 | $1.76M derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2018-06-30 | $1.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | -$511.00K 10-Q · filed 2018-08-09 | $1.86M derived: sum of 3 quarters · filed 2019-05-09 | -$503.00K derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2018-03-31 | -$2.21M 10-Q · filed 2019-05-09 | $163.00K derived: sum of 2 quarters · filed 2019-05-09 | -$2.20M derived: sum of 3 quarters · filed 2019-05-09 | -$93.00K derived: sum of 4 quarters · filed 2019-05-09 | ||
| 2017-12-31 | $2.37M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $8.00K derived: sum of 2 quarters · filed 2019-03-01 | $2.11M derived: sum of 3 quarters · filed 2019-03-01 | $1.17M 10-K · filed 2019-03-01 | ||
| 2017-09-30 | -$2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | -$256.00K derived: sum of 2 quarters · filed 2018-11-08 | -$1.20M 10-Q · filed 2018-11-08 | -$9.27M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-06-30 | $2.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $1.16M 10-Q · filed 2018-08-09 | -$6.91M derived: sum of 3 quarters · filed 2019-03-01 | -$1.20M derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2017-03-31 | -$942.00K 10-Q · filed 2018-05-10 | -$9.02M derived: sum of 2 quarters · filed 2019-03-01 | -$3.31M derived: sum of 3 quarters · filed 2019-03-01 | $304.00K derived: sum of 4 quarters · filed 2019-03-01 | ||
| 2016-12-31 | -$8.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | -$2.37M derived: sum of 2 quarters · filed 2019-03-01 | $1.25M derived: sum of 3 quarters · filed 2019-03-01 | $859.00K 10-K · filed 2019-03-01 | ||
| 2016-09-30 | $5.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $9.32M derived: sum of 2 quarters · filed 2017-11-09 | $8.93M 10-Q · filed 2017-11-09 | $9.70M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-06-30 | $3.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $3.22M 10-Q · filed 2017-08-08 | $3.99M derived: sum of 3 quarters · filed 2018-03-01 | $2.03M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-03-31 | -$387.00K 10-Q · filed 2017-05-10 | $377.00K derived: sum of 2 quarters · filed 2018-03-01 | -$1.58M derived: sum of 3 quarters · filed 2018-03-01 | -$463.00K derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2015-12-31 | $764.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | -$1.20M derived: sum of 2 quarters · filed 2018-03-01 | -$76.00K derived: sum of 3 quarters · filed 2018-03-01 | $1.01M 10-K · filed 2018-03-01 | ||
| 2015-09-30 | -$1.96M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$840.00K derived: sum of 2 quarters · filed 2016-11-09 | $247.00K 10-Q · filed 2016-11-09 | -$149.00K derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-06-30 | $1.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $2.21M 10-Q · filed 2016-08-09 | $1.81M derived: sum of 3 quarters · filed 2017-03-16 | $1.03M derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2015-03-31 | $1.09M 10-Q · filed 2016-05-10 | $691.00K derived: sum of 2 quarters · filed 2017-03-16 | -$92.00K derived: sum of 3 quarters · filed 2017-03-16 | $874.00K derived: sum of 4 quarters · filed 2017-03-16 | ||
| 2014-12-31 | -$396.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$1.18M derived: sum of 2 quarters · filed 2017-03-16 | -$213.00K derived: sum of 3 quarters · filed 2017-03-16 | -$1.03M 10-K · filed 2017-03-16 | ||
| 2014-09-30 | -$783.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-09 | $183.00K derived: sum of 2 quarters · filed 2015-11-09 | -$634.00K 10-Q · filed 2015-11-09 | -$400.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-06-30 | $966.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-10 | $149.00K 10-Q · filed 2015-08-10 | $383.00K derived: sum of 3 quarters · filed 2016-03-15 | -$183.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2014-03-31 | -$817.00K 10-Q · filed 2015-05-11 | -$583.00K derived: sum of 2 quarters · filed 2016-03-15 | -$1.15M derived: sum of 3 quarters · filed 2016-03-15 | -$714.00K derived: sum of 4 quarters · filed 2016-03-15 | ||
| 2013-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$332.00K derived: sum of 2 quarters · filed 2016-03-15 | $103.00K derived: sum of 3 quarters · filed 2016-03-15 | -$136.00K 10-K · filed 2016-03-15 | ||
| 2013-09-30 | -$566.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-10 | -$131.00K derived: sum of 2 quarters · filed 2014-11-10 | -$370.00K 10-Q · filed 2014-11-10 | $90.00K derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2013-06-30 | $435.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $196.00K 10-Q · filed 2014-08-11 | $656.00K derived: sum of 3 quarters · filed 2015-03-16 | -$5.55M derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2013-03-31 | -$239.00K 10-Q · filed 2014-05-12 | $221.00K derived: sum of 2 quarters · filed 2015-03-16 | -$5.99M derived: sum of 3 quarters · filed 2015-03-16 | -$15.52M derived: sum of 4 quarters · filed 2015-03-16 | ||
| 2012-12-31 | $460.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$5.75M derived: sum of 2 quarters · filed 2015-03-16 | -$15.28M derived: sum of 3 quarters · filed 2015-03-16 | -$2.48M 10-K · filed 2015-03-16 | ||
| 2012-09-30 | -$6.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-07 | -$15.74M derived: sum of 2 quarters · filed 2013-11-07 | -$2.94M 10-Q · filed 2013-11-07 | -$3.83M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-06-30 | -$9.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | $3.26M 10-Q · filed 2013-08-09 | $2.38M derived: sum of 3 quarters · filed 2014-03-13 | $3.11M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2012-03-31 | $12.80M 10-Q · filed 2013-05-09 | $11.91M derived: sum of 2 quarters · filed 2014-03-13 | $12.64M derived: sum of 3 quarters · filed 2014-03-13 | $12.88M derived: sum of 4 quarters · filed 2014-03-13 | ||
| 2011-12-31 | -$883.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-13 | -$154.00K derived: sum of 2 quarters · filed 2014-03-13 | $84.00K derived: sum of 3 quarters · filed 2014-03-13 | $727.00K 10-K · filed 2014-03-13 | ||
| 2011-09-30 | $729.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09 | $967.00K derived: sum of 2 quarters · filed 2012-11-09 | $1.61M 10-Q · filed 2012-11-09 | $2.09M derived: sum of 4 quarters · filed 2013-03-18 | $4.89M 10-Q · filed 2011-11-08 | |
| 2011-06-30 | $238.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-07 | $881.00K 10-Q · filed 2012-08-07 | $1.36M derived: sum of 3 quarters · filed 2013-03-18 | $1.29M derived: sum of 4 quarters · filed 2013-03-18 | $4.16M 10-Q · filed 2011-08-09 | |
| 2011-03-31 | $643.00K 10-Q · filed 2012-05-10 | $1.13M derived: sum of 2 quarters · filed 2013-03-18 | $1.05M derived: sum of 3 quarters · filed 2013-03-18 | |||
| 2010-12-31 | $482.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $405.00K derived: sum of 2 quarters · filed 2013-03-18 | $2.46M 10-K · filed 2013-03-18 | |||
| 2010-09-30 | -$77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-08 | $1.98M 10-Q · filed 2011-11-08 | ||||
| 2010-06-30 | $2.05M 10-Q · filed 2011-08-09 | |||||
| 2009-12-31 | -$11.91M 10-K · filed 2012-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |